These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 32237644)
1. [Are the two formulas of Levothyrox bioequivalent?]. Coste J; Bertagna X; Zureik M; Nicolas P; Ramez P; Hill C; Schlumberger M Rev Prat; 2019 Oct; 69(8):831-837. PubMed ID: 32237644 [No Abstract] [Full Text] [Related]
2. [Both formulas of Levothyrox are not bioequivalent]. Hill C; Schlumberger M Rev Prat; 2019 Jun; 69(6):599-601. PubMed ID: 31626414 [No Abstract] [Full Text] [Related]
3. Spontaneous adverse event notifications by patients subsequent to the marketing of a new formulation of Levothyrox Viard D; Parassol-Girard N; Romani S; Van Obberghen E; Rocher F; Berriri S; Drici MD Fundam Clin Pharmacol; 2019 Aug; 33(4):463-470. PubMed ID: 30575110 [TBL] [Abstract][Full Text] [Related]
5. Impact of the "French Levothyrox crisis" on signal detection in the World Health Organization pharmacovigilance database. Khouri C; Revol B; Lepelley M; Mallaret M; Cracowski JL Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1427-1428. PubMed ID: 30379373 [No Abstract] [Full Text] [Related]
6. The French Levothyrox Mouly S; Roustit M; Bagheri H; Perault-Pochat MC; Molimard M; Bordet R Therapie; 2019 Jun; 74(3):431-435. PubMed ID: 30737052 [No Abstract] [Full Text] [Related]
8. The equivalency of two L-thyroxine preparations. Hennessey JV; Burman KD; Wartofsky L Ann Intern Med; 1985 Jun; 102(6):770-3. PubMed ID: 3922270 [TBL] [Abstract][Full Text] [Related]
9. New levothyroxine formulation meeting 95-105% specification over the whole shelf-life: results from two pharmacokinetic trials. Gottwald-Hostalek U; Uhl W; Wolna P; Kahaly GJ Curr Med Res Opin; 2017 Feb; 33(2):169-174. PubMed ID: 27718637 [TBL] [Abstract][Full Text] [Related]
10. Comparative bioavailability of two oral L-thyroxine formulations after multiple dose administration in patients with hypothyroidism and its relation with therapeutic endpoints and dissolution profiles. Vaisman M; Spina LD; Eksterman LF; dos Santos MJ; Lima JS; Volpato NM; da Silva RL; de Brito AP; Noël F Arzneimittelforschung; 2001; 51(3):246-52. PubMed ID: 11304941 [TBL] [Abstract][Full Text] [Related]
17. Biosimilar medical products - licensing, pharmacovigilance and interchangeability. Grozdanova A; Netkovska KA; Sterjev Z; Naumovska Z; Zarevski R; Dimovski A; Suturkova L Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2016; 37(1):27-36. PubMed ID: 27442414 [TBL] [Abstract][Full Text] [Related]
18. Nonequality of brand name thyroxine preparations. Jacobson JM; Ramos-Gabatin A; Young RL; Watkins SC; Brown ML JAMA; 1980 Feb 22-29; 243(8):733. PubMed ID: 7351814 [No Abstract] [Full Text] [Related]
19. The Regulation of Biosimilars in Latin America. Garcia R; Araujo DV Curr Rheumatol Rep; 2016 Mar; 18(3):16. PubMed ID: 26951254 [TBL] [Abstract][Full Text] [Related]
20. Bioequivalence of two levothyroxine tablet formulations without and with mathematical adjustment for basal thyroxine levels in healthy Argentinian volunteers: a single-dose, randomized, open-label, crossover study. Di Girolamo G; Keller GA; de Los Santos AR; Schere D; Gonzalez CD Clin Ther; 2008 Nov; 30(11):2015-23. PubMed ID: 19108789 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]